AZN News

Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis

Microplastics Discovered in Prostate Tumors

Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology's Most Critical Questions

PorTal Access, Inc. Appoints Industry Veteran David Snow to Board of Directors to Advance Next-Generation Oncology Vascular Access Solutions

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer

Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

Glucagon-like Peptide 1 (GLP-1) Market Report 2026-2035: Market to Reach $33.26 Billion by 2030 - Oral Formulations and Long-Acting Peptides Accelerate Next-Gen Obesity and Diabetes Therapies

ZERO Prostate Cancer Announces 2026 Prostate Cancer Summit and Veterans Action Convening to Improve Care and Outcomes for Veterans

Complement C5 Inhibitors & C5 Receptor Antagonists Pipeline Market Research Report 2026: Soliris and Ultomiris from AstraZeneca and Piasky Have Set the Stage for Next Generation Biosuperiors